The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Mozax, don't know, it tried to break through 0.90 twice, maybe 3rd time lucky?
Arron sounded bullish in the RNS, for me it was "certainty" of more contracts tb signed by June end; if it does indeed happen, then yes, SP should return to +1p.
Won’t take much to set this alight, sellers have disappeared & it seems stock is tight.
Argyle, they bought in at 0.80...last week SP was 0.63...they paid a 27% premium to last week's SP, NOT a discount; and, most of us here ARE long term investors, hence our points about licensing revenues coming etc, which some others dismiss as "JAM tomorrow".
I have been posting since February that there will be no placing (mainly because there are revenues coming in regularly, at small sums adding up and thus not RNSed) and I have been adding small lots too.
Perhaps there’s a whiff of news regarding something ‘material’.
Cornerstone investors get 1st dibs at the best prices LT. Just means they see long term value at these prices and have the capital to risk.
It's 26mln, it seems i.e. 5.6% so an RNS should follow in the next few days; maybe these guys are not "aware of the imminent Placing" !! :))))))
That's a large holding changing hands....
FROM THE FT ----https://www.ft.com/content/a7cb45a5-c2d7-4d7f-81f4-e4922d79b6c7-----
Is this good for Apta's (expected!) LTF tests? Or complementary to it? LTF helping diagnosis, vaccine treating it?
"Japan’s Takeda Pharmaceuticals has reached a deal worth up to $2.2bn to develop an Alzheimer’s vaccine made by Swiss start-up AC Immune, as drug companies race to invest in potentially lucrative new treatments for the disease. The vaccine is one of a wave of new drugs heading for the market, including lecanemab, developed by Japanese company Eisai, which received US regulatory approval last year. In the Takeda deal, AC Immune will receive an upfront payment of $100mn, rising to $2.1bn if milestones are reached, as well as more than 10 per cent in royalties from any worldwide sales. The Japanese group could advance the product to late-stage, phase 3 trials, AC Immune said, but regulatory approval could take several years. Early trials had identified no safety concerns, said Andrea Pfeifer, chief executive of the biotech. But AC Immune would not have efficacy data for the drug until it completed a mid-stage trial within the next 12 months..."
Talking about "pump", I forgot to mention UNILEVER too (revenues in a couple of years, plus fee-for service until we get there); :)))))
A good run of pump now is the order of the day before discounted placing.
Only a few weeks left now, either cash has actually come into the bank on paid orders or it hasn’t.
The figures need to do the talking now, nothing else counts.
They can talk, talk talk about how great the POTENTIAL is and the size of the dollop of JAM but if all your business drops off and nobody is paying you its going to be one hell of a hard sell for further investment. Results in H1 were absolutely shocking.
Lets see what comes in as fully paid up, if its derisory again, SH will need to dig deep to keep it going.
Just to add that the IPO-Mkt cap of 80mln was mainly predicated on these licensing deals' potential, rather than the fee-for service; as we know, the Co run out of cash in the meantime and the edifice came down; however, the potential is still there, we just had a delay in execution.
GLA
Thanks AR. IMO (rather biased!), there will be no Placing this year as the cash - at end of Jan - sufficed to Aug-Sept, WITH NO SALES/INCOME from thereon (which is highly unlikely, given the 4.5 mln pipeline and signed deals so far); also, at any time from today until the Autumn, there could potentially be a licensing deal (up to 6-8 mln were mentioned 3 months ago); although this would be for the medium term, the impact would fall straight to Profit (i.e. no WCapital needed), plus there would be profile-raising, more approaches for business etc, so I hope a Placing would no be needed; we know (announced) that licensing deals could be close with the Top 5 and 15 Pharmas, also with Neuro-bio for the LTFs (within 2024, was mentioned in the Interims Presentation), plus NOVAVX has a licensing potential; plus others we may not know about.
All IMO.
LT it pays to ignore any reference to pipeline or potential deals here and just concentrate on those signed, which still, as you rightly acknowledge, take a little time to convert to revenues.
As with all AIM/growing companies, they tend to emphasise positives rather than the harder realities (i.e. bank balance) which does sometimes make it harder to track where exactly things are financially.
We know from Arrons twitter chats that with the cash in hand and signed deals, they should have a runway until December with nothing new added.
Since February we only know that they've been working through their order book , but what the exact figures are only they know.
Everyone here knows the potential of APTA, it's just about the time taken/funds needed either raised or from trading in order to get there.
My guess (hope?) is that they will look to fundraise from a position of recently signed deal strength in the late summer/autumn.
ARich, thanks for the additional numbers info. I chose the 5 Febr. one as I thought 3 months would provide a better comparison, but your numbers are also useful. The "discrepancies" are - just IMO - due to the fact that the numbers are dynamic, not static; for example if today I sign a deal, from the adn stage ones, it leaves the advanced stage total and becomes a signed one; also, when the signed one gets processed, it turns into revenues; I think the Co has not told us about Revenues since february, just signed deals and pipeline; this might explain the differences. But should I assume zero processing/revenues since February?
LT why do you chose to ignore this from the interims, 28th March?
"The Company expects to progress the £1.3 million of signed work and a proportion of an additional £2.9 million of contracts in advanced-stage negotiations through the laboratory before the end of the financial year"
This shows £0.9m rise in pipeline between 5th Feb to 28th March and £0.1m increase between 28th March and today.
For reference, the pipeline was £11.7m on 21.03.23.
@ArgRich, I think there is one more difference - back on Feb 5th, it was:
"over £1.4 million of signed deals either being or to be processed through the laboratory. ....a pipeline of opportunities ...£2.0 million in medium-term deals. Approx £1.5 million of the medium-term deals are advanced stage....", so - IMO - a total of 2.9mln of signed/adv.stage deals;
Now, this has risen (in 3 months) to "... pipeline is strong, with OVER £3.0 million in advanced stage discussions", plus the 1.4mln of signed deals, meaning a 1.5 mln rise (min) in adv-stage deals; and we also assume that since Febr 5 (3 months ago) there has been ZERO processing of signed deals (which is not reasonable); here I mean that even thought the 1.4mln number is the same over 3 months, it can be the case that some of this has been processed (turning into REVENUES), and an equivalent amount has moved from the adv-stage deals' number to signed deals (IMO);
But the main plus from today is the comment that more contracts will be signed /announced in the next weeks (to June end).
Aptamer remains firmly focussed on the first of these three objectives and is pleased to report progress on the second two objectives.
Since the announcement of the half year results, the Group has made significant progress in regarding its new platform technology, Optimer®+, through an initial soft launch and agreement of the first commercial sale.
Patents have been filed to protect the Optimer binders developed in partnership with Unilever for use in cosmetics applications to support ongoing commercial discussions between the two companies, with further testing underway. A follow-on deal has been signed with Neuro-Bio to develop a second Optimer binder to enable a wholly Optimer-powered lateral flow test for the early detection of Alzheimer's disease. Furthermore, the Group has made significant progress in the precision gene therapy space, demonstrating Optimer performance in lab-based tests as drug delivery vehicles specific to the cells associated with fibrotic liver disease and establishing chemical manufacturing methods for scaled test batches. These Optimer-conjugates are currently undergoing evaluation by a top 15 pharma partner, with additional negotiations underway with a major top 10 pharmaceutical company to explore the Optimer-conjugates as part of a proof-of-concept study.
The Group's current sales pipeline is strong, with over £3.0 million in advanced stage discussions. A proportion of these advanced stage deal negotiations is anticipated to progress through the laboratory before the end of the financial year. This anticipated deal value is in addition to the c.£1.4m of existing signed deals already at various stages of completion in the production laboratory. Revenue recognition on all signed deals is further subject to the receipt of target material in a timely manner from customers, and scientific attrition.
The only thing that looks to different is £1.4m of signed deals at various stages of advancement as opposed to £1.3m at the Interims.
Yes, my thoughts exactly, his excitement got the better of him & he couldn’t help himself!
The Nomad got involved quickly.
A trading update with no new updates. It looks like Arron got his knuckles rapped for Friday's material/non-material tweet.
100% agreed LTB....First stage ....the placing price of 1.1p.
Second.....into orbit. ...its coming!
I think it's gonna be too late for those waiting ("hoping"?) for a Placing at 0.50p , before they buy in - IMO
As I said last week, "SP will be over 1p in next 2-3 months" - but that might a bit too conservative an estimate!
The future is looking very promising.. patience is going to be rewarded.
Https://www.investegate.co.uk/announcement/rns/aptamer-group--apta/trading-update/8191515
"The Group's current sales pipeline is strong, with over £3.0 million in advanced stage discussions. A proportion of these advanced stage deal negotiations is anticipated to progress through the laboratory before the end of the financial year. This anticipated deal value is in addition to the c.£1.4m of existing signed deals..."
"The Company looks forward to providing further updates on conversion of the pipeline to contracts before the year end"; this means more RNSs in the next 6 weeks (to June end).